在中风后预防认知衰退的oxiracetam和体育活动:多中心随机对照试验
Jae-Sung Lim1, Joung-Ho Rha2, Jong-Ho Park3,4
1Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
European stroke journal
|August 29, 2025
概括
在高风险患者中,oxiracetam 没有预防中风后认知障碍 (PSCI). 这项研究没有发现显著的益处,支持在韩国暂停使用.
科学领域:
- 神经学
- 神经科学
- 药理学
背景情况:
- 脑卒中后认知障碍 (PSCI) 是患者康复的一个重要问题.
- 牛津对其预防PSCI的能力进行了研究.
- 这项研究还探讨了oxiracetam与体力活动之间的相互作用.
研究的目的:
- 评估oxiracetam在预防中风后认知障碍 (PSCI) 的有效性.
- 在中风幸存者中研究氧化与体力活动之间的潜在相互作用.
- 通过神经成像来评估oxiracetam对认知功能的影响.
主要方法:
- 这是一项多中心,双盲,安慰剂对照试验,涉及500名高风险患者.
- 参与者接受了36周的氧化或安慰剂治疗.
- 使用MMSE和CDR- SB评估认知功能,并通过动图监测身体活动.
主要成果:
- 在oxiracetam和安慰剂组之间没有发现微型精神状态检查 (MMSE) 或临床痴呆症评分总和 (CDR- SB) 的统计学意义上的差异.
- 在oxiracetam和身体活动之间没有观察到相互作用.
- 探索性分析表明,在高度活跃的oxiracetam参与者中出现了潜在的积极趋势.
结论:
- 在高危人群中,oxiracetam对预防PSCI没有益处.
- 这些发现与韩国最近暂停使用oxiracetam的监管决定一致.
- 进一步的研究可能会探讨特定的子组或干预措施.
相关概念视频
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206